U.S. markets close in 6 hours 25 minutes

GSK plc (GSK)

NYSE - Nasdaq Real Time Price. Currency in USD
35.41+0.51 (+1.46%)
As of 09:35AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close34.90
Bid35.49 x 2200
Ask35.53 x 1100
Day's Range35.40 - 35.50
52 Week Range28.47 - 46.97
Avg. Volume3,652,398
Market Cap72.822B
Beta (5Y Monthly)0.27
PE Ratio (TTM)13.31
EPS (TTM)2.66
Earnings DateFeb 01, 2017 - Feb 06, 2017
Forward Dividend & Yield1.48 (4.24%)
Ex-Dividend DateFeb 23, 2023
1y Target Est44.11
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
-2% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for GSK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • GSK plc
    Analyst Report: GSK PLCGSK plc, based in Brentford, UK, is a global healthcare company engaged in the discovery, development, manufacture and marketing of pharmaceutical products. The company's leading products include treatments for asthma and COPD; products for HIV infection; and a range of vaccines. The company has active research and development programs in immuno-inflammation, neuroscience, metabolic pathways, ophthalmology, respiratory and infectious diseases, and biopharmaceuticals.
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • Benzinga

    Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case' Executives at GSK Plc (NYSE: GSK), Moderna Inc (NASDAQ: MRNA), and CSL Seqirus, owned by CSL Ltd (OTC: CSLLY), said they are developing or about to test sample human vaccines against bird flu as a precautionary measure against a future pandemic. Others, like Sanofi SA (NASDAQ: SNY), said they "stand ready" to begin production if needed, w

  • InvestorPlace

    3 Pharma Stocks That Could Benefit from Global Healthcare Trends

    When it comes to finding good pharma stocks to buy, I try to focus on companies that are developing drugs that can help huge numbers of people. After all, high profits are the ultimate key catalyst for stocks, and it’s much easier for companies to generate gigantic profits if there is a huge demand for the products they are developing. The following three drug stocks certainly fit that criterion. One has a very promising treatment for cancer, which is a leading cause of death in both the U.S. an

  • Motley Fool

    Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?

    No vaccine has been approved to prevent respiratory syncytial virus (RSV), but there are more than 30 different RSV vaccine candidates in clinical trials, according to PATH, a global health organization. Research from the Centers for Disease Control and Prevention (CDC) estimate that between 60,000 and 160,000 adults 65 and older are hospitalized each year with RSV, and 6,000 to 10,000 older adults die because of it. One to two out of every 100 children younger than 6 months of age with an RSV infection may need to be hospitalized.